This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Dividendos de Diffusion Pharmaceuticals

Dividendo controles de criterios 0/6

Diffusion Pharmaceuticals does not have a record of paying a dividend.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$6.41
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02

Aug 12

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Feb 25

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Nov 12

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Jun 25

Diffusion Pharmaceuticals EPS misses by $0.02

May 10

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Mar 08

Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Nov 23

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: Insufficient data to determine if DFFN's dividends per share have been stable in the past.

Dividendo creciente: Insufficient data to determine if DFFN's dividend payments have been increasing.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Diffusion Pharmaceuticals vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de DFFN con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (DFFN)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.7%
Media de la industria (Biotechs)	2.8%
Previsión de analistas en 3 años (DFFN)	n/a

Dividendo destacado: Unable to evaluate DFFN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Alto dividendo: Unable to evaluate DFFN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Pago de beneficios a los accionistas

Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Unable to calculate sustainability of dividends as DFFN has not reported any payouts.

This company is no longer active

Dividendos de Diffusion Pharmaceuticals

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

EIP Pharma, Inc. completed the acquisition of Diffusion Pharmaceuticals Inc. (NasdaqCM:DFFN) in a reverse merger transaction.

Diffusion Pharmaceuticals Inc. Announces Resignation of William K. Hornung as CFO

Diffusion Pharmaceuticals Inc. Announces Resignation of Christopher D. Galloway as Chief Medical Officer, Effective March 1, 2023

High number of new and inexperienced directors

LifeSci Special Opportunities Master Fund Ltd Issues an Open Letter to Shareholders of Diffusion Pharmaceuticals Inc

High number of new and inexperienced directors

Diffusion Pharmaceuticals Inc. Announces Resignation of Eric Francois from the Board of Directors and All Committees and Subcommittees

Diffusion Pharmaceuticals Inc., Annual General Meeting, Dec 30, 2022

Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger as Chief Regulatory Officer

Diffusion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$100.00

High number of new and inexperienced directors

Diffusion Pharmaceuticals Announces 1-For-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

High number of new and inexperienced directors

High number of new and inexperienced directors

Diffusion Pharmaceuticals Inc. Announces Board Appointments

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

Diffusion Pharmaceuticals Inc. Doses First Participants in Altitude Trial

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Diffusion Pharmaceuticals Inc. Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division

Co-Founder & Director John Gainer has left the company

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Diffusion Pharmaceuticals Inc. Reports Final Results from Its Phase 1B Study of Trans Sodium Crocetinate in Hospitalized Covid-19 Patients

Diffusion Pharmaceuticals EPS misses by $0.02

Diffusion Pharmaceuticals Doses First Participants in TCOM Study

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

New 90-day high: US$1.49

New 90-day high: US$1.04

Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Price target lowered to US$2.00

New 90-day low: US$0.75

Diffusion Pharmaceuticals Inc. Appoints Christopher D. Galloway as Chief Medical Officer

Diffusion Pharmaceuticals Appoints William Elder as General Counsel and Corporate Secretary

Diffusion Pharmaceuticals Names Dr. Robert Cobuzzi as Chief Executive Officer

New 90-day low - US$0.78

New 90-day high - US$1.47

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies